• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CalciMedica Inc.

    6/24/25 4:32:33 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALC alert in real time by email
    S-8 1 d949209ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 24, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    CalciMedica, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   45-2120079

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    505 Coast Boulevard South, Suite 307

    La Jolla, California

      92037
    (Address of Principal Executive Offices)   (Zip Code)

    2023 Equity Incentive Plan

    2023 Employee Stock Purchase Plan

    (Full titles of the plans)

    A. Rachel Leheny, Ph.D.

    Chief Executive Officer

    505 Coast Boulevard South, Suite 307

    La Jolla, California 92037

    (858) 952-5500

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Thomas A. Coll

    Carlos Ramirez

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    (858) 550-6000

     

    John M. Dunn

    General Counsel

    505 Coast Boulevard South, Suite 307

    La Jolla, California 92037

    (858) 952-5500

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated Filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    This Registration Statement on Form S-8 is being filed by CalciMedica, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “SEC”) for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective. The Registrant previously registered its shares of common stock, par value $0.0001 per share, for issuance under (i) the Registrant’s 2023 Employee Stock Purchase Plan under the Registrant’s Registration Statements on Form S-8 filed with the SEC on May  12, 2023 (File No. 333-271898) and March 28, 2024 (File No. 333-278336) (collectively, the “Registration Statements”) and (ii) the Registrant’s 2023 Equity Incentive Plan under the Registration Statements and the Registrant’s Registration Statement on Form S-8 filed with the SEC on August 27, 2024 (File No. 333-281800) (together with the Registration Statements, the “Prior Registration Statements”). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements.

    ITEM 8. EXHIBITS.

     

    Exhibit
    Number
      

    Description

     4.1    Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
     4.2    Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
     4.3    Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020).
     5.1    Opinion of Cooley LLP.
    23.1    Consent of Independent Registered Public Accounting Firm.
    23.2    Consent of Cooley LLP. Reference is made to Exhibit 5.1.
    24.1    Power of Attorney. Reference is made to the signature page hereto.
    99.1    CalciMedica, Inc. 2023 Equity Incentive Plan.
    99.2    Form of Option Grant Notice and Option Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
    99.3    Forms of Restricted Stock Unit Grant Notice and Unit Award Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
    99.4    CalciMedica, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.9 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on May 12, 2023).
    107    Filing Fee Table.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of La Jolla, State of California, on June 24, 2025.

     

    CALCIMEDICA, INC.
    By:   /s/ A. Rachel Leheny, Ph.D.
      A. Rachel Leheny, Ph.D.
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints A. Rachel Leheny, Ph.D. and Stephen Bardin, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable CalciMedica, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.


    Signature

      

    Title

     

    Date

    /S/ A. RACHEL LEHENY, PH.D.

    A. Rachel Leheny, Ph.D.

       Chief Executive Officer and Director
    (Principal Executive Officer)
      June 24, 2025

    /S/ STEPHEN BARDIN

    Stephen Bardin

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      June 24, 2025

    /S/ ROBERT N. WILSON

    Robert N. Wilson

       Chairman   June 24, 2025

    /S/ ALAN GLICKLICH, M.D.

    Alan Glicklich

       Director   June 24, 2025

    /S/ FREDERIC GUERARD, PHARM.D.

    Frederic Guerard, Pharm.D.

       Director   June 24, 2025

    /S/ FRED MIDDLETON

    Fred Middleton

       Director   June 24, 2025

    /S/ ERIC W. ROBERTS

    Eric W. Roberts

       Director   June 24, 2025

    /S/ ALLAN SHAW

    Allan Shaw

       Director   June 24, 2025
    Get the next $CALC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CALC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CALC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

      Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc analysis of patients in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia who had AKI with respiratory failure at enrollment LA JOLLA, Calif., June 25, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a publication in the American Journal of Nephrology (AJN) highlighting the design and rationale of th

      6/25/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

      LA JOLLA, Calif., June 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, Italy. Details for the oral presentations to be presented during the sympo

      6/12/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      5/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Stauderman Kenneth A. bought $1,850 worth of shares (1,000 units at $1.85) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      7/2/25 9:48:24 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF BUSINESS OFFICER Roberts Eric W bought $6,483 worth of shares (4,500 units at $1.44) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      6/27/25 7:35:22 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Hebbar Sudarshan

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      6/26/25 6:31:33 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Stauderman Kenneth A. bought $1,850 worth of shares (1,000 units at $1.85) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      7/2/25 9:48:24 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF BUSINESS OFFICER Roberts Eric W bought $6,483 worth of shares (4,500 units at $1.44) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      6/27/25 7:35:22 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Bardin Stephen bought $3,005 worth of shares (2,000 units at $1.50) (SEC Form 4)

      4 - CalciMedica, Inc. (0001534133) (Issuer)

      6/26/25 6:30:22 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    SEC Filings

    See more
    • SEC Form S-8 POS filed by CalciMedica Inc.

      S-8 POS - CalciMedica, Inc. (0001534133) (Filer)

      6/27/25 4:03:04 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by CalciMedica Inc.

      8-K - CalciMedica, Inc. (0001534133) (Filer)

      6/27/25 4:01:25 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by CalciMedica Inc.

      S-8 - CalciMedica, Inc. (0001534133) (Filer)

      6/24/25 4:32:33 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Leadership Updates

    Live Leadership Updates

    See more
    • CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      5/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

      Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

      3/27/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

      LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D. to the Company's Board of Directors effective on January 15, 2025. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics.

      1/14/25 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Financials

    Live finance-specific insights

    See more
    • CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

      Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m. PT LA JOL

      10/30/24 7:00:00 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

      Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutt

      10/28/24 4:05:00 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

      Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.

      8/12/24 4:10:00 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by CalciMedica Inc.

      SC 13D - CalciMedica, Inc. (0001534133) (Subject)

      11/26/24 6:03:55 AM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      11/14/24 3:32:39 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

      SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

      11/14/24 1:05:20 PM ET
      $CALC
      Biotechnology: Pharmaceutical Preparations
      Health Care